Last reviewed · How we verify

QUINIDINE — Competitive Intelligence Brief

QUINIDINE (QUINIDINE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

marketed sigma-1 receptor, NMDA receptor, CYP2D6 Small molecule Live · refreshed every 30 min

Target snapshot

QUINIDINE (QUINIDINE). Dextromethorphan acts as a sigma-1 receptor agonist and NMDA receptor antagonist, while quinidine increases its plasma levels by inhibiting CYP2D6.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
QUINIDINE TARGET QUINIDINE marketed sigma-1 receptor, NMDA receptor, CYP2D6 1950-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). QUINIDINE — Competitive Intelligence Brief. https://druglandscape.com/ci/quinidine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: